PharmAthene, Inc. ' Product Pipeline Review ' 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

PharmAthene, Inc. ' Product Pipeline Review ' 2012
Published on August 2012

Report Summary


Summary

Global Markets Direct's pharmaceuticals report, 'PharmAthene, Inc. - Product Pipeline Review - 2012' provides data on the
PharmAthene, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete
with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, PharmAthene, Inc.'s
corporate website, SEC filings, investor presentations and featured press releases, both from PharmAthene, Inc. and industry-specific
third party sources, put together by Global Markets Direct's team.

Scope

- PharmAthene, Inc. - Brief PharmAthene, Inc. overview including business description, key information and facts, and its locations
and subsidiaries.
- Review of current pipeline of PharmAthene, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of PharmAthene, Inc. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PharmAthene, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate PharmAthene, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PharmAthene, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PharmAthene, Inc.'s R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PharmAthene, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PharmAthene, Inc. and identify potential opportunities in those areas.

PharmAthene, Inc. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
PharmAthene, Inc. Snapshot 5
PharmAthene, Inc. Overview 5
Key Information 5
Key Facts 5
PharmAthene, Inc. ' Research and Development Overview 6
Key Therapeutic Areas 6
PharmAthene, Inc. ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
PharmAthene, Inc. ' Pipeline Products Glance 10
PharmAthene, Inc. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
PharmAthene, Inc. ' Drug Profiles 11
Protexia 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Valortim 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
PharmAthene, Inc. ' Pipeline Products by Route of Administration 14
PharmAthene, Inc. ' Pipeline Products By Mechanism of Action 15
PharmAthene, Inc. ' Recent Pipeline Updates 16
PharmAthene, Inc. - Dormant Projects 18
PharmAthene, Inc. ' Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
PharmAthene, Inc., Recent Developments 20
PharmAthene, Inc.- Press Release 20
Aug 10, 2012: PharmAthene Receives FDA Notification On SparVax 20
Jun 14, 2012: PharmAthene Reports Further Progress In Development Of SparVax Anthrax Vaccine Program 20
Apr 12, 2012: PharmAthene Presents Update On SparVax rPA Anthrax Vaccine Program At 2012 World Vaccine Congress 21
Dec 07, 2009: PharmAthene Announces Phase I Clinical Trial Results And New Therapeutic Animal Model Data Of Protexia 22
Dec 07, 2009: PharmAthene Presents Phase I Clinical Trial Results And New Therapeutic Animal Model Data For Protexia 23
Sep 03, 2009: PharmAthene Presents Data For Valortim At The Bacillus ACT 2009 Conference 24
Jul 09, 2009: PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax, Completes FDA Regulatory Strategy Review 25
May 22, 2009: PharmAthene Submits SparVax Regulatory Strategy To FDA 26
Apr 28, 2009: PharmAthene Announces to Host A Conference To Provide An Update On The SparVax rPA Anthrax Vaccine Program
26



Apr 28, 2009: PharmAthene Presents Data For SparVax At The 12th Annual Conference On Vaccine Research 26
Feb 24, 2009: PharmAthene Presents Data For SparVax At The 7th Annual ASM Biodefense Meeting 27
Feb 24, 2009: PharmAthene Presents Data For Valortim At The 7th Annual ASM Biodefense Meeting 27
Financial Deals Landscape 29
PharmAthene, Inc., Deals Summary 29
PharmAthene, Inc., Pharmaceuticals & Healthcare, Deal Details 30
Asset Transactions 30
PharmAthene Acquires Vaccines Business From Avecia Biologics 30
Partnerships 32
GTC Biotherapeutics Enters Into An Agreement With Pharmathene 32
Licensing Agreements 34
GTC Biotherapeutics Extends Licensing Agreement With PharmAthene 34
Equity Offering 36
PharmAthene Files Shelf Registration Statement For Public Offering Of $100 Million 36
PharmAthene Completes Registered Direct Offering Of $6.5 Million 37
PharmAthene Completes Over-Allotment Option Of Registered Public Offering For $17.3 Million 39
PharmAthene Completes Public Offering Of $5.5 Million 45
Debt Offering 47
PharmAthene Completes Private Placement Of $19.3 Million 47
Acquisition 49
Healthcare Acquisition Completes Reverse Acquisition Of PharmAthene 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables

PharmAthene, Inc., Key Information 5
PharmAthene, Inc., Key Facts 5
PharmAthene, Inc. ' Pipeline by Indication, 2012 7
PharmAthene, Inc. ' Pipeline by Stage of Development, 2012 8
PharmAthene, Inc. ' Monotherapy Products in Pipeline, 2012 9
PharmAthene, Inc. ' Phase I, 2012 10
PharmAthene, Inc. ' Pipeline By Route of Administration, 2012 14
PharmAthene, Inc. ' Pipeline Products By Mechanism of Action, 2012 15
PharmAthene, Inc. ' Recent Pipeline Updates, 2012 16
PharmAthene, Inc. - Dormant Developmental Projects,2012 18
PharmAthene, Inc., Subsidiaries 19
PharmAthene, Inc., Deals Summary 29
PharmAthene Acquires Vaccines Business From Avecia Biologics 30
GTC Biotherapeutics Enters Into An Agreement With Pharmathene 32



GTC Biotherapeutics Extends Licensing Agreement With PharmAthene 34
PharmAthene Files Shelf Registration Statement For Public Offering Of $100 Million 36
PharmAthene Completes Over-Allotment Option Of Registered Public Offering For $17.3 Million 39
PharmAthene Completes Public Offering Of $5.5 Million 45
PharmAthene Completes Private Placement Of $19.3 Million 47
Healthcare Acquisition Completes Reverse Acquisition Of PharmAthene 49

List of Figures

PharmAthene, Inc. ' Pipeline by Indication, 2012 7
PharmAthene, Inc. ' Pipeline by Stage of Development, 2012 8
PharmAthene, Inc. ' Monotherapy Products in Pipeline, 2012 9
PharmAthene, Inc. ' Pipeline By Route of Administration, 2012 14


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 1 500.00 Quantity: _____

Site License--USD 3 000.00 Quantity: _____

Corporate License--USD 4 500.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


PharmAthene, Inc. ' Product Pipeline Review ' 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

PharmAthene, Inc. ' Product Pipeline Review ' 2012